Corvus Pharmaceuticals, Inc. (CRVS) stock

CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30

$10.64+0.02 (+0.19%)

Close on Nov 13, 2026Market cap $895.05MP/E –Yield –

Corvus Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Corvus Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?